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Abstract
Background: Our prospective pilot study of acupuncture affecting insulin sensitivity on polycystic ovary syndrome
(PCOS) combined with insulin resistance (IR) showed that acupuncture had a significant effect on improving the
insulin sensitivity of PCOS. But there is still no randomized controlled trial to determine the effect of acupuncture
on the insulin sensitivity in women with PCOS and IR. In this article, we present the protocol of a randomized
controlled trial to compare the effect of true acupuncture on the insulin sensitivity of these patients compared with
metformin and sham acupuncture. Acupuncture may be an effective therapeutic alternative that is superior to
metformin and sham acupuncture in improving the insulin sensitivity of PCOS combined with IR.
Methods: This study is a multi-center, controlled, double-blind, and randomized clinical trial aiming to evaluate the
effect of acupuncture on the insulin sensitivity in PCOS combined with IR. In total 342 patients diagnosed with PCOS
and IR will be enrolled. Participants will be randomized to one of the three groups: (1) true acupuncture +metformin
placebo; (2) sham acupuncture +metformin, and (3) sham acupuncture +metformin placebo. Participants and
assessors will be blinded. The acupuncture intervention will be given 3 days per week for a total of 48 treatment
sessions during 4 months. Metformin (0.5 g per pill) or placebo will be given, three times per day, and for 4 months.
Primary outcome measures are changes in homeostasis model assessment of insulin resistance (HOMA-IR) and
improvement rate of HOMA-IR by oral glucose tolerance test (OGTT) and insulin releasing test (Ins). Secondary
outcome measures are homeostasis model assessment-β (HOMA-β), area under the curve for glucose and insulin,
frequency of regular menstrual cycles and ovulation, body composition, metabolic profile, hormonal profile,
questionnaires, side effect profile, and expectation and credibility of treatment.
Outcome measures are collected at baseline, at the end of treatments, and 3 months after the last acupuncture
treatment. On completion of the screening visit, randomization will be conducted using a central randomization
system.
Discussion: This study will investigate the effects of acupuncture on the insulin sensitivity of PCOS and IR women
compared with metformin and sham acupuncture. We will test whether true acupuncture with needles placed in
skeletal muscles and stimulated manually and by electrical stimulation is more effective than metformin and sham
acupuncture with superficial needle placement with no manual or electrical stimulation in improving the insulin
sensitivity in PCOS women with IR.
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Background
Polycystic ovary syndrome (PCOS) is one of the most
common endocrine disorders in reproductive age
women. It is characterized by chronic anovulation and
hyperandrogenism and is often accompanied by obesity
and insulin resistance (IR) as IR is present in nearly 40%
of PCOS [1]. In addition, IR, hyperinsulinemia, and dyslip-
idemia worsen with aging, and the risk of miscarriage is
three times higher than in healthy women [2]. They are
also at an increased risk of pregnancy complications such
as impaired glucose tolerance, gestational diabetes melli-
tus, pregnancy-induced hypertension and preeclampsia,
and small for gestational age children [2]. It may affect
general health and the quality of life. Both hyperandrogen-
ism and IR contribute to the pathogenesis of many aspects
of PCOS [3, 4].
IR in PCOS results from hyperinsulinemia and defects
in the insulin signaling pathway. Further, high concentra-
tions of insulin reduce circulating levels of sex hormone
binding globulin (SHBG) and increase levels of free testos-
terone, and the latter leads to menstrual disturbance,
development of ovarian cysts, hirsutism, and anovulatory
infertility [5]. IR leads to a higher risk of impaired glucose,
type 2 diabetes, dyslipidemia, atherosclerosis, and vascular
disease [6].
The first-line treatment for overweight or obese
women with PCOS is modification of diet and lifestyle.
This confirmed that the benefit of improved ovulation
and live birth with delayed infertility treatment with
clomiphene citrate when preceded by lifestyle modifica-
tion with weight loss was superior to immediate treatment
[7], but for many subjects it is not easy to sustain [8].
Treatments of IR with insulin-sensitizing agents have been
used in women with PCOS [9]. Metformin, an insulin-
sensitizing agent known to decrease hepatic glucose pro-
duction via a transient inhibition of the mitochondrial
respiratory-chain complex 1 and an activation of the
AMP-activated protein kinase (a cellular metabolic sensor
[10]), improves irregular menstrual cycles in women with
PCOS whether IR is present or not [11]. Nevertheless, it is
not effective in treating hirsutism, acne, or anovulatory in-
fertility [12]. It also has side effects such as gastrointestinal
irritation (diarrhea and nausea) and lactic acidosis, which
is rare but serious [13]. In addition, metformin is not
recommended for patients with kidney, lung, liver, and
heart disease or on a low-carbohydrate diet [14]. Other
common insulin-sensitizing agents are thiazolidinediones,
including troglitazone (which is no longer available for
clinical use), rosiglitazone, and pioglitazone [15]. However,
rosiglitazone may result in cardiovascular diseases [16],
and pioglitazone may increase the risk of bladder cancer
[17]. Both may double the risk of bone fractures [18].
Given that current pharmacological treatments have such
side effects, there is an urgent need to find a better and
safer therapy for IR in PCOS women.
As an integrated part of Traditional Chinese Medicine
and a relatively safe treatment [19], acupuncture treat-
ment for PCOS has gained increasing attention in recent
years. The effect of acupuncture is most likely mediated
via activation of sensory nerve fibers, which in turn
modulate the sympathetic activity to the ovaries and in
the central nervous system [20, 21]. A review found that
acupuncture can correct various metabolic disorders con-
tributing to the development of IR, such as hyperglycemia,
overweight, hyperphagia, hyperlipidemia, inflammation,
altered activity of the sympathetic nervous system, and
insulin signal defect [22]. Thus, acupuncture may have the
potential to improve insulin sensitivity [22]. Other findings
suggest that electrical acupuncture stimulation affects
more functional signaling pathways related to insulin
sensitivity, while manual stimulation of acupuncture
needles has a greater effect on glucose tolerance [23]. Fur-
thermore, in female insulin-resistant rats both electrical
and manual acupuncture stimulation enhances insulin
sensitivity via activation of sensory afferents [24]. Our pro-
spective pilot study (ClinicalTrials.gov NCT02026323)
[25] of acupuncture affecting the insulin sensitivity in 81
cases of women with PCOS with IR showed that acu-
puncture has a significant effect on improving the
insulin sensitivity in these patients. But there is still
no randomized controlled trial to determine the effect
of acupuncture on insulin sensitivity in women with
PCOS combined with IR.
Thus, we present the protocol of a randomized
controlled trial to investigate the effects of acupuncture
on the insulin sensitivity of women with PCOS com-
bined with IR. We hypothesize that true acupuncture is
superior to metformin and sham acupuncture in im-
proving insulin sensitivity.
Objectives
The primary objective of this randomized controlled trial
is to evaluate the hypothesis that true acupuncture +met-
formin placebo (group 1) improves insulin sensitivity, as
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measured by changes in the homeostasis model assess-
ment of insulin resistance (HOMA-IR), more effectively
than sham acupuncture +metformin (group 2) and sham
acupuncture +metformin placebo (group 3) in women
with PCOS and IR. Secondary objectives include changes
in HOMA-β (islet β-cell function), C-peptide index, the
insulin response to glucose calculated from the oral glu-
cose tolerance test (OGTT) and insulin releasing test
(Ins), frequency of the regular menstrual cycle and ovula-
tion, circulating sex steroids, lipid profile, health-related
quality of life and symptoms of anxiety and depression,
side effects, and credibility.
Methods
Overview
This is a randomized controlled trial to determine the
effect of true acupuncture + metformin placebo for the
improvement of insulin sensitivity in women with PCOS
and IR compared with sham acupuncture + metformin
and sham acupuncture +metformin placebo. The design
of this study is compliant with the Consolidated Standards
of Reporting Trials (CONSORT) guidelines [26] and with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) statement 2013 [27] [see
Additional file 1].
Patients and enrollment
Women with PCOS and IR will be recruited from the
Department of Traditional Chinese Medicine in the First
Affiliated Hospital of Guangzhou Medical University,
Xuzhou Maternity & Child Health Hospital, Dalian
Municipal Women and Children’s Medical Center,
Guangdong Women and Children’s Hospital, and Hexian
Memorial Affiliated Hospital of Southern Medical Univer-
sity if they meet the inclusion criteria and do not have any
exclusion criteria. Eligible subjects will be approached and
sign the consent form after detailed explanation of the
study design and comprehensive counseling (see the flow
diagram in Fig. 1).
Inclusion Criteria
(1)Chinese women aged from 18 to 40 years.
(2)Body mass index (BMI) ≥18.5 kg/m2.
(3)Confirmed diagnosis of PCOS according to the
Rotterdam criteria in 2003 including at least
two of the following three features: (1) oligo-
(an intermenstrual interval >35 days or <8 cycles in
the past year) or amenorrhea (an intermenstrual
interval >90 days), and/or (2) polycystic ovarian
morphology, i.e., presence of >12 antral follicles
(≤9 mm) and/or ovarian volume >10 ml on
ultrasonography scanning, and/or (3) clinical and/or
biochemical hyperandrogenism. Clinical
hyperandrogenism on the Chinese Mainland is
defined as a Ferriman-Gallwey (FG) score ≥5 [28];
biochemical hyperandrogenism is total testosterone
(T) >2.6 nmol/l and free testosterone ≥6.0 pg/ml [29].
(4)Presence of IR as defined by the homeostatic model
assessment—HOMA-IR: [fasting insulin (μU/ml) ×
fasting glucose (mmol/l)] / 22.5). A value ≥2.14 is
considered to be indicative of IR [30].
(5)No immediate fertility wish and willingness to use
barrier contraceptive methods for 7 months.
(6)Willingness to sign the consent form.
Exclusion Criteria
(1)Exclusion of other endocrine disorders:
(1)Uncorrected thyroid disease (defined as thyroid
stimulating hormone (TSH) < 0.2 mIU/ml or
>5.5 mIU/ml, triiodothyronine (T3) < 1.4 nmol/l
or >2.2 nmol/l, and free thyroxine (T4) < 10
pmol/l or >23 pmol/l). A normal level within the
last year is adequate for entry.
(2)Poorly controlled type I or type II diabetes
(defined as a glycosylated hemoglobin (HbA1c)
level >7.0%) or patients receiving antidiabetic
medications such as insulin, thiazolidinediones,
acarbose, or sulfonylureas likely to confound the
effects of the study medication; patients
currently receiving metformin XR (extended
release) for a diagnosis of type I or type II
diabetes or for PCOS are also excluded.
(3)Cushing’s syndrome (defined as an archetype of
metabolism syndrome. High glucocorticoid levels
lead to muscle, liver, and adipocyte insulin
resistance; 17-hydorxycorticosteroids >55 umol/
24 h or urinary-free cortisol >304 nmol/24 h).
(4)Congenital adrenal hyperplasia (defined as patients
with known 21-hydroxylasedeficiency or other
enzyme deficiency leading to the phenotype of
congenital adrenal hyperplasia; 17-oh progester-
one >10 ng/ml in adrenocorticotropic hormone 1-
24 h excited test (after 60 min).
(5)Suspected androgen-secreting adrenal or ovarian
tumor.
(2)Use of hormonal or other medication including Chinese
herbal prescriptions, which may affect the outcome of
the last 2 months.
(3)Receiving acupuncture in the past 2 months.
(4)Within 6 weeks of pregnancy.
(5)Post-abortion or postpartum within the past 6 weeks.
(6)Breastfeeding within the last 4 months.
(7)Not willing to give written consent to the study.
(8)Having a bariatric surgery procedure within the past
12 months or being in a period of acute weight loss.
(9)Additional exclusion criteria include:
a. Patients on oral contraceptives, depot progestin,
or hormonal implants (including Implanon). A
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2-month washout period will be required prior
to screening for patients on these agents. Longer
washouts may be necessary for certain depot
contraceptive forms or implants, especially
where the implants are still in place. A 1-month
washout will be required for patients on oral
cyclic progestin.
b. Heart disease.
c. Patients with a history of or suspected cervical
carcinoma, endometrial carcinoma, or breast
carcinoma.
d. Patients enrolled in other studies that require
medications.
e. Patients taking longer than a 1-month break
during the protocol should not be enrolled.
Intervention arms
Information to all study subjects
All participants will be advised about the importance of
regular physical exercise and a balanced diet by a trained
dietician before they receive the treatments. Importantly,
they are instructed not to change their exercise or diet
habits during the entire study period.
True acupuncture or sham acupuncture and metformin
will be started 2 days after the baseline visit including
OGTT and Ins. All subjects will be asked to use a barrier
method for contraception. True and sham acupuncture
treatment will be given three times per week. Each treat-
ment session lasts for 30 min and can be separated by an
interval of 1-3 days, with a maximum of 48 treatment
sessions during 4 months. After the third treatment, all
patients fill in the expectation and credibility questionnaire
[31]. Metformin (0.5 g per pill) or placebo will be given,
three times per day for 4 months.
True acupuncture protocol
The rationale of acupuncture protocols is based on trad-
itional Chinese and Western medical theories, and the
study protocol follows the CONSORT [26] and Standards
for Reporting Interventions in Clinical Trials of Acupunc-
ture (STRICTA) [32] recommendations. We will use fixed
acupuncture protocols. The acupuncture protocol of this
randomized controlled trial (RCT) follows the protocol in
the previous RCT in women with PCOS including Acu-
puncture to Treat Insulin Resistance in Women With and
Fig. 1 CONSORT flow diagram of the study. PCOS polycystic ovary syndrome; HOMA homeostatic model assessment; IR insulin resistance;
AUC area under the curve
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Without Polycystic Ovary Syndrome (ClinicalTrials.gov
NCT01457209) [33], Acupuncture and Clomiphene Cit-
rate on Live Birth in Anovulatory Women With Polycystic
Ovary Syndrome (ClinicalTrials.govNCT01573858) [34],
and a prospective pilot study of the Effect of Acupuncture
on Insulin Sensitivity Polycystic Ovary Syndrome (Clinical-
Trials.gov NCT02026323) [25].
Disposable, single-use, sterilized needles made of stain-
less steel, 0.25 × 30 mm and 0.30 × 40/50 mm (Huanqiu,
Suzhou Huanqiu Acupuncture Medical Instrument Co.,
Ltd. 215002 Suzhou, China), will be inserted to a depth
of 15–35 mm in segmental acupuncture points located
in abdominal and leg muscles with innervations corre-
sponding to the ovaries. Two sets of acupuncture points
will be alternated every second treatment (Table 1 [25]).
The first set consists of the conception vessel (CV) 3,
CV 12, and stomach (ST) 29 bilaterally and in the mus-
cles above the knee, ST34, and ST 33 bilaterally and
below the knee, spleen (SP) 6, and ST 36. Needles will
also be placed in extra-segmental acupuncture points
that do not innervate the ovaries large intestine (LI) 4
bilaterally. In total, 14 needles will be placed, and all will
be stimulated manually by rotating the needle to evoke
needle sensation (de qi) once when inserted. The follow-
ing points will be connected to an electrical stimulator
(Export Abteilung, Schwa-Medico GmbH, Wetzlarer Str.
41-43; 35630 Ehringshausen): CV 3 to CV 12, ST 29 bi-
lateral, and ST 34 to ST 33 bilateral. Stimulations are
Table 1 Acupuncture protocol [25]
Point Stimulation location Muscle Innervation
Set 1
Zhongji (CV3) EA 4 cun caudal to the umbilicus Fibrous tissue, linea alba L1
Zhongwan (CV12) EA On the midline, 4 cun superior to the umbilicus Fibrous tissue, linea alba Th7-8
Guilai (bilateral) (ST29) EA 1 cun cranial to the pubic bone and 2 cun lateral
of the midline
M. rectus abdominis Th6-12
Liangqiu (bilateral) (ST34) EA 2 cun above the superior lateral border of the
patella on the line connecting the anterior
superior iliac spine found with the knee flexed
M. quadriceps femoris Femoral
nerve
Yinshi (bilateral) (ST33) EA 3 cun above the superior lateral border of the
patella on the line connecting the anterior
superior iliac spine found with the knee flexed
M. quadriceps femoris Femoral
nerve
Sanyinjiao (bilateral) (SP6) De Qi four
times
3 cun proximal to the medial malleolus Mm. flexor digitorum longus, tibialis
posterior
L4–5, S1–2
Zusanli (bilateral) (ST36) De Qi four
times
On the anterior lateral side of the leg, 3 cun
below Dubi (ST35), one finger width
(middle finger) from the anterior crest of the tibia
Musculi tibialis anterior L4–5, S1
Hegu (bilateral) (LI4) De Qi four
times




Daju (bilateral) (ST27) EA 3 cun cranial to the pubic bone and 2 cun
lateral to the midline
M. rectus abdominis Th6–12
Qihai (CV6) EA 1.5 cun caudal to the umbilicus Fibrous tissue, linea alba Th11
Xiawan (CV10) EA 2 cun cranial to the umbilicus Fibrous tissue, linea alba Th8
Extra-meridian point (bilateral) EA 6 cun above the patella in line with SP10 M. quadriceps femoris L2–L4
Xuehai (bilateral) (SP10) EA With the knee flexed, on the medial side of
the thigh 2 cun above the superior medial
corner of the patella on the prominence of
the medial head of the quadriceps
muscle of the thigh
M. quadriceps femoris L2–L4
Sanyinjiao (bilateral) (SP6) De Qi four
times
3 cun proximal to the medial malleolus Mm. flexor digitorum longus, tibialis
posterior
L4–5, S1–2
Taichong (bilateral) (LR3) De Qi four
times
Between metatarsal I & II, just distal to
the caput
M. interosseus dorsalis I S2–3
Neiguan (bilateral) (PC6) De Qi four
times
2 cun proximal to the processus styloideus
radii, between the tendons of the palmaris
longus and the flexor carpi radialis
M. flexor digitorum superficialis C8, Th1
The two sets will be alternated for every other treatment
C cervical vertebra, CV conception vessel, EA electroacupuncture, L lumbar vertebra, LI large intestine, LR liver, M. musculi, Mm. musculus, PC pericardium, S sacral
vertebra, SP spleen, ST stomach, Th thoracic vertebra
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given as low-frequency electric acupuncture (EA) of
2Hz, 0.3 ms pulse length, with an intensity adjusted to
produce local muscle contractions without pain or dis-
comfort. Needles not connected to the electrical stimula-
tor will be manually stimulated to evoke needle
sensation every 10 min, in total four times. The second
set consists of 14 needles placed in segmental abdominal
points and stimulated electrically: ST 27 bilaterally, CV
6 connected to CV 10; leg points: SP10 connected to a
non-acupuncture point located 6 cun proximal to the
patella as the medial border (electrical stimulation); SP 6
and liver (LR) 3 bilaterally (manual stimulation). Extra-
segmental points are pericardium (PC) 6 bilaterally
(manual stimulation).
Needle insertion technique
Needle insertion should be gentle. The skin is tightened
by pressing around the area of needle insertion, and the
needle is then gently inserted.
Needles and stimulation
Needle size: 0.25 × 30 mm or 0.30 × 40 or 0.30 × 50 mm.
Select needle length with respect to the patients’ BMI:
0.25 × 30-mm needles in women with normal BMI,
0.30 × 40-mm needles in overweight women, and 0.30 ×
50 or 75-mm needles in obese women. Depth of inser-
tion may vary from patient to patient. Needles are placed
with a depth deep enough to reach muscle/fibrous
tissue. When a needle is inserted, the needle is stimulated
gently until de qi (needle sensation reflecting activation of
sensory afferents). As soon as de qi has been reached, the
needle does not hurt or cause any pain and discomfort.
Manual stimulation of needles that are not attached to an
electrical stimulator is stimulated when inserted, after
10 min, 20 min, and immediately before they are removed
after 30 min.
The electrodes are attached to an electric stimula-
tion according to the protocol. The electric stimulator
is turned on to program 10, and the intensity is grad-
ually increased. The intensity will be as high as possible
without causing pain or discomfort of subjects. The
stimulation amplitude/intensity will be adjusted after 10
and 20 min at the same time as when manually stimulated
needles are manipulated. After 30 min the stimulator is
turned off, electrodes are disconnected, and needles are
taken out.
Sham acupuncture protocol
Disposable, single-use, sterilized needles made of stainless
steel, 0.20 × 20 mm (Huanqiu, Suzhou Huanqiu Acupunc-
ture Medical Instrument Co., Ltd. 215002 Suzhou, China)
will be inserted superficially to a depth of <5 mm, one in
each shoulder and one in each upper arm at non-
acupuncture points (Table 2 [34]) with no stimulation.
Placement of needles is unlikely to affect ovulation and IR
in women with PCOS. Electrodes will be attached to the
needles, and the stimulator will be turned on at an inten-
sity of zero (no active current) to mimic EA in the acu-
puncture protocol. No manual stimulation of the needles
will be performed. An intended adjustment of the inten-
sity is made after 10 min, 20 min, and again after 30 min
when the stimulator is turned off and the needles
removed.
True and sham acupuncture treatment
(1)Time of the day and the name of the acupuncturist
when the patient receives acupuncture will be
recorded.
(2)The intensity of stimulation (mA) is noted. It may
vary between different electrodes. Note the range,
e.g., 1.2 – 3.0 mA.
(3)Note any other events that may affect the treatment
(positive or negative).
(4)Note concomitant medications.
(5)Collect menstrual logs at the end of every cycle.
Metformin and placebo
Metformin (Bristol-Myers Squibb Co., Shanghai, China)
and placebo tablets (Jaden Pharmaceutical Co., Ltd.,
Guangzhou, China) will be packed and tested by a com-
mercial pharmacy supply company (Panlongyunhai
Pharmaceutical Co., Kunming, Yunnan, China) specifically
for this study. Metformin or placebo will be started 2 days
after the baseline visit including OGTT and Ins. Subjects
will take 0.5 g/time, three times per day for 4 months. If
the patients have adverse effects such as nausea and dizzi-
ness, the dose will be reduced to 0.5 g/time, two times or
one time per day according to the severity.
Monitoring and examination during the treatment
All subjects will be instructed not to change their phys-
ical exercise habits or diet during the entire study. They
are asked to use barrier contraception, not hormonal
contraception. Physical examination will be performed
monthly. Every menstruation should be recorded,
Table 2 Sham acupuncture protocol [34]
Point Stimulation location Skin innervation
No known point Sham EA On top of acromion C3-4, n. supraclavicularis
No known point Sham EA On humerus, behind LI14 C5-6, n. cutaneous brachii lateralis
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including the date, volume, and duration of menstruation
during the entire study and follow-up. The conditions of
physical exercise and diet will be recorded for every cycle.
Study-specific visits and procedures
Patients will attend five visits, including the screening
visit, baseline measurements, treatment visit, after-
treatment measurements, and follow-up measurements.
Months indicate when each specific measurement takes
place. Adverse events and concomitant medications will
be recorded during every visit. The overview of study
visits is shown in Table 3.
Screening visit
Women are screened in the morning after an overnight
12-h fast. Detailed information about the study design is
given.
Obtain signed informed consent
Complete physical examination Complete physical
examinations will be performed including height, weight,
hip, and waist measurements. Height and weight will be
recorded to the nearest 0.1 cun and 0.1 kg, respectively.
Waist and hip circumference will be recorded to the
nearest 1 cun. Hirsute assessment by FG, acne standard
acne lesion counts, and pelvic examination will be
conducted.
Perform transvaginal or transrectal ultrasound of ovaries
Ovaries, including the ovarian size in three dimensions,
the size of the largest ovarian follicle/cyst and size of
every follicle with a mean diameter greater than 10 mm,
and total antral follicle count (small follicles with mean
diameter <10 mm) of each ovary will be obtained
through transvaginal or transrectal ultrasound.
Check urine pregnancy test
Fasting blood samples to exclude other endocrine
disorders Fasting (at least 4 h) blood samples are taken
to exclude any endocrine disorders:
Fasting glucose, fasting insulin, HbA1C (>7%), C-
peptide, TSH (<0.2 mIU/ml or >5.5 mIU/ml), T3
(<1.4 nmol/l or >2.2 nmol/l), and free T4 (<10 pmol/l or
>23 pmol/l).
Progestin withdrawal
Provide progestin prescription to induce withdrawal
bleeding, with instructions to begin medication once
eligibility has been determined.
Baseline visit
After the screening visit, if a woman fulfills inclusion
criteria and has signed the informed consent form, she
will be assigned to the baseline visit. The baseline visit
takes place day 2–5 of a spontaneous period or after a
withdrawal bleeding after an overnight fast.
Laboratory Examination
Blood will be collected. Part of it will be stored, and the
remainder is used for determination of DNA and
sphingolipid levels.
(1)Circulating sex steroids: Fasting serum levels of
follicle-stimulating hormone (FSH), luteinizing
hormone (LH), estradiol (E2), prolactin (PRL)
and T, and sex hormone binding globulin (SHBG).
Table 3 Overview of study visits




visit 3 months after
the last acupuncture
treatment
1st 2nd 3rd 4th
OGTT and Ins √ √ √
Body composition (weight, height, waist circumference,
hip circumference, FG/acne)
√ √ √ √ √ √ √ √
Menstrual cycle diary √ √ √ √ √ √ √ √
Fasting blood samples for FGLU, FINS, HbA1c, C-peptide,
TSH, T3, free T4
√
Fasting blood samples for FSH, LH, SHBG, T, E2, PRL √ √ √
Fasting blood samples for ApoA1,ApoB, TC, TG, HDL-C,
LDL-C, BRT, renal and liver profile
√ √ √
Transvaginal or transrectal ultrasound √ √ √
Questionnaires √ √ √
Apoa1 apolipoprotein A1, ApoB apolipoprotein B, BRT blood routine test, E2 estradiol, FG Ferriman-Gallwey score, FGLU fasting blood glucose, FINS Fasting insulin,
FSH follicle-stimulating hormone, HbA1c glycosylated hemoglobin, HDL-C high density lipoprotein, LDL-C low density lipoprotein, LH luteinizing hormone, PRL
prolactin, SHBG sex hormone-binding globulin, T total testosterone, TC total cholesterol, TG triglyceride, TSH thyroid stimulating hormone, T3 triiodothyronine, T4
thyroxine, OGTT oral glucose tolerance test, Ins insulin-releasing test
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(2)Lipid profile: Triglycerides (TG), total cholesterol
(TC), high-density lipoprotein (HDL-C), low-density
lipoprotein (LDL-C), apolipoprotein A1 (ApoA1),
apolipoprotein B (ApoB), blood routine test(BRT),
and renal and liver profiles.
(3)Glucose homeostasis and insulin sensitivity: The
OGTT and Ins with 75 g glucose. Blood samples will
be obtained to measure plasma glucose, serum
insulin, and C-peptide at 0, 60, and 120 min
during the OGTT and Ins.
Complete questionnaires
Quality of life will be assessed by the short form 36 (SF-
36) [35], the Chinese Quality of Life (ChiQOL) [36],
sleeping questionnaires [37], international physical activ-
ity questionnaire (IPAQ) [38], questionnaire of eating
and weight patterns (QEWP) [39], and the Polycystic
Ovary Syndrome Questionnaire (PCOS-QOL) [40]. We
will also assess symptoms of anxiety and depression by
the Zung SAS and Zung SDS questionnaires and
complete the quantization table of traditional Chinese
medicine (TCM) syndromes about PCOS.
Assess TCM syndromes of patients
Syndrome differentiation (Bian Zheng) in TCM is the
comprehensive analysis of clinical information gained by
the four main diagnostic TCM procedures: observation,
listening, questioning, and pulse analysis, and it is used
to guide the choice of treatment by acupuncture and/
or TCM herbal formulae [41]. In PCOS, patients are
empirically differentiated into four categories: (1) phlegm-
dampness syndrome, (2) blood stasis syndrome, (3)
phlegm, and (4) blood stasis.
Visit after 4 months of acupuncture treatment
During the end of treatment visit, all baseline measures
will be repeated as listed below:
(1)Physical examination will be performed, including
vital signs, height, weight, and hip and waist
measurements as well as repeating hirsute and acne
assessments after the end of treatment or pregnancy.
(2)The serum levels of sex hormone steroids and the
metabolic profile will be repeated.
(3)The transvaginal or transrectal ultrasound will be
repeated for antral follicle counts.
(4)OGTT and Ins will be repeated.
(5)Blood will be collected for storage and for
determination of DNA and sphingolipid levels.
(6)QOL, sleeping, IPAQ, anxiety/depression
questionnaires, QEWP, and the quantization
table of TCM will be repeated.
(7)Menstrual logs will be collected.
(8)Adverse events and concomitant medications
will be recorded.
(9)The questionnaires about acupuncture treatment
will be answered.
End of treatment visit
The end of treatment visit will be done 3 months after
the last acupuncture treatment (see points 1-8 under
Visit after 4 months of acupuncture treatment). All the
subjects will be followed up by visiting the acupunctur-
ists monthly for 3 months. The conditions of physical
exercise and diet will be record every month.
Safety analysis
Adverse events will be categorized and the percentage of
patients experiencing adverse events and serious adverse
events during the treatment period and follow-up period
will be documented and reported to the Data and Safety
Monitoring Board (DSMB). These will be reviewed on a
quarterly basis by the DSMB, and serious adverse events





(1)Improvement rate of HOMA-IR.
(2)HOMA-β: Islet β-cell function will be evaluated by
the formula (20 × fasting insulin (mU/ml) / (fasting
plasma glucose (mmol/l) − 3.5)) [42] and by the
C-peptide index (CPI) Fasting C-peptide (nmol/l)/f-
glucose (mmol/l) × 100 [43].
(3)The insulin response to glucose will be assessed by
calculating the area under the curve during the
OGTT and Ins performance for glucose (AUCglu)
and insulin (AUCins) using the trapezoidal rule [44].
(4)Frequency of menstrual cycles and ovulation.
(5)Body composition: weight, BMI, waist-to-hip
circumference, and FG and acne lesion counts.
(6)Metabolic profile: glucose and insulin
concentrations, C-peptide, HbA1c, TC, TG, HDL-C
and LDL-C, and ApoA1 and ApoB.
(7)Hormonal profile: FSH, LH, T, and SHBG.
(8)Questionnaires: SF-36, ChiQOL, sleeping question-
naires, IPAQ,QEWP, PCOS-QOL, Zung SAS, Zung
SDS questionnaires, and the quantization table of
TCM syndromes about PCOS will be used to assess
the quality of life and sleep and the emotional state
and to measure the moderate physical activity.
(9)Side effect profile.
(10) Expectation and credibility of treatment.
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Data management and quality control of data
Both the Case Record Form (CRF) and web-based
electronic database will be used to manage individual
participant data. Quality control of the data will be
handled at two different levels: the investigators will
be required to ensure the accuracy of the data as the
first level of control when they input the records in CRF.
The second level will include data monitoring and valid-
ation that will be carried out by an independent group. A
web-based electronic database, ResMan (www.medres-
man.org), is used as a double input database. Finally,
the individual participant data except the private in-
formation will be allowed to be share with the public
within 6 months after the trial completion.
Sample size calculations
In our pilot study [25] evaluating the effect of acu-
puncture on insulin sensitivity in PCOS women with
IR, HOMA-IR reduced significantly after 3 months of
acupuncture treatment when an interim analysis was
performed and changed from (4.3 ± 2.5) vs. (3.7 ± 2.1).
HOMA-IR ≥2.14 was considered to be abnormal. We
anticipate that the HOMA-IR after 4 months of true
acupuncture treatment will decrease 25%, and sham
acupuncture will be decreased 5% as it is well known
that sham is not an inert procedure. Therefore, the
difference is 20%, with two-sided α assigned to be 5%
and β 20% at the upper limit, respectively, at which
the power is 80% and the rate of attrition estimated
to be 20%. Thus, the sample size has been inflated
from 95 to 114 per group, totaling 342 cases for the
three arms. The sample size was calculated using the
software statistics toolkit supported by the Department of
Obstetrics and Gynecology of the Chinese University
of Hong Kong (http://www.obg.cuhk.edu.hk/Research-
Support/StatTools/index.php).
Randomization and patient allocation
Subjects will be randomly allocated into one of the three
treatment arms by a 1:1:1 treatment ratio: (1) true acu-
puncture + metformin placebo, (2) sham acupuncture +
metformin, and (3) sham acupuncture +metformin pla-
cebo. The Data Coordination Centre (DCC) statisticians
will generate the randomization scheme for the study.
The true and sham acupuncture treatments will be
known only to the acupuncturists besides the DCC data
manager. The metformin and placebo having the same
package will be organized in a kit consisting of 4 sacks
for each subject with 336 tablets in total, respectively.
The kit will be labeled with an ID number mapped to
the metformin and placebo known only to the DCC
personnel. The metformin and placebo assignments will
be double-blind to any site investigators.
A central randomization system will be used to allo-
cate patients. Patients will be stratified based on three
sites and randomly assigned. The Chinese Clinical Trial
Registry takes the responsibility for generation of the
random number sequence by computer software, and
the allocation sequence is deposited in ResMan, a web-
based database. When a new participant enrolls, the
allocation information will be obtained by inputting a
special password in ResMan. It is not possible to specu-
late the allocation status of the participant before getting
the information.
Statistical analysis strategy
The Kolmogorov-Smirnov test will be used to test the
normal distribution of continuous variables. Continuous
variables will be presented by mean ± standard deviation
if they are normally distributed or by median with inter-
quartile range if they are not normally distributed. Both
per protocol (PP) analysis and intention-to-treat analysis
(ITT) will be used to determine the robustness of the
evidence. Analysis of variance (ANOVA) with Bonferroni
corrections will be used for comparing the differences
between groups of continuous data in accordance with a
normal distribution or Kruskal-Wallis test for non-normal
distribution data when appropriate; χ2 tests will be used
for comparison of dichotomous data. For the primary out-
come, analysis of covariance (ANCOVA) (accompanying
LSMEAN and 95% CI) will be used. ANOVA will be used
to calculate the changes from baseline to after treatment
and follow-up, respectively, and it will also be used to
compare the differences between treatment arms with
respect to the primary outcome, HOMA-IR. Effect of con-
tinuous data will be reported by both P-value and mean
difference with 95% confidence interval and categorical
data by P-value and relative risk (RR) and risk difference
(RD) with 95% confidence interval; the number needed to
treat (NNT) will be calculated if there is statistical signifi-
cance between groups. All statistical analyses of the data
will be performed by using SPSS software version 21.0
(SPSS Inc., Chicago, IL, USA).
Discussion
Although we have confirmed that the combination of man-
ual and low frequency EA can improve insulin sensitivity,
hormone levels, and anxiety situation in patients with
PCOS by the prospective study (ClinicalTrials.gov
NCT02026323) [25], it had the limitation of being a single
center study without comparison groups. There is still a
lack of high-quality studies to determine the effect of acu-
puncture on insulin sensitivity in PCOS women and IR.
Based on the results of the prospective observational
study (ClinicalTrials.gov NCT02026323) [25], we designed
this randomized, double-blind, placebo-controlled, and
multi-center study protocol to evaluate whether
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acupuncture treatment is more effective than metformin
and sham acupuncture in improving the insulin sensitivity
of PCOS and IR. The use of a larger sample size in a ran-
domized setting, controlled by sham acupuncture and com-
mon medicine of insulin-sensitizing agents, will reduce the
risk of type II error. Therefore, the results of this study may
provide evidence for using acupuncture in future clinical
practice in this area.
Trial status
The study was registered at ClinicalTrials.gov on 24 June
2015. Recruitment was started on 11 November 2015
and is expected to end in March 2018. Recruitment is
ongoing and 114 participants were randomized as of the
end of December 2016. The final report will be available
in 2018.
Additional file
Additional file 1: SPIRIT 2013 checklist. Recommended items to address
in a clinical trial protocol and related documents. (PDF 106 kb)
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